Current Stem Cell Research & Therapy,
Год журнала:
2023,
Номер
19(10), С. 1303 - 1311
Опубликована: Окт. 17, 2023
In
the
last
decade,
liver
diseases
with
high
mortality
rates
have
become
one
of
most
important
health
problems
in
world.
Organ
transplantation
is
currently
considered
effective
treatment
for
compensatory
failure.
An
increasing
number
patients
and
shortage
donors
has
led
to
attention
reconstructive
medicine
methods
researchers.
The
biggest
challenge
development
drugs
chronic
disease
lack
a
suitable
preclinical
model
that
can
mimic
microenvironment
problems.
Organoid
technology
rapidly
evolving
field
enables
researchers
reconstruct,
evaluate,
manipulate
intricate
biological
processes
Expert Review of Gastroenterology & Hepatology,
Год журнала:
2023,
Номер
17(3), С. 237 - 249
Опубликована: Янв. 24, 2023
According
to
the
recent
updates
from
World
Health
Organization,
liver
diseases
are
12th
most
common
cause
of
mortality.
Currently,
orthotopic
transplantation
(OLT)
is
effective
and
only
treatment
for
end-stage
diseases.
Owing
several
shortcomings
like
finite
numbers
healthy
organ
donors,
lifelong
immunosuppression,
complexity
procedure,
cell
cell-derivatives
therapies
have
emerged
as
a
potential
therapeutic
alternative
Various
types
been
proposed
their
effects
evaluated
in
preclinical
or
clinical
studies,
including
hepatocytes,
hepatocyte-like
cells
(HLCs)
derived
stem
cells,
human
(HLSCs),
combination
with
various
organoids,
implantable
cell-biomaterial
constructs
synthetic
natural
polymers
even
decellularized
extracellular
matrix
(ECM).In
this
review,
we
highlighted
current
status
cell-derivative-based
Furthermore,
discussed
future
prospects
using
HLCs,
therapies.Promising
application
cell-based
techniques
iPSC
technology
has
integrated
into
novel
such
gene
editing,
directed
differentiation,
organoid
technology.
iPSCs
offer
promising
represent
strategies
modeling
PLoS ONE,
Год журнала:
2023,
Номер
18(8), С. e0289798 - e0289798
Опубликована: Авг. 8, 2023
Liver
transplantation
is
the
most
effective
treatment
option
for
patients
with
acute
or
chronic
liver
failure.
However,
applicability
and
effectiveness
of
this
modality
are
often
limited
by
a
shortage
donors,
surgical
complications,
high
medical
costs,
need
continuing
immunosuppressive
therapy.
An
alternative
approach
cell
transplantation.
LIGHT
(a
member
tumor
necrosis
factor
superfamily)
could
be
promising
candidate
promoting
differentiation
human
bone
marrow-derived
mesenchymal
stem
cells
(hBM-MSCs)
into
hepatocyte-like
cells.
In
study,
we
investigated
effect
on
hBM-MSC
Our
previous
results
showed
that
receptor
lymphotoxin-β
(LTβR)
constitutively
expressed
surface
hBM-MSCs.
Upon
recombinant
(rhLIGHT),
phenotype
hBM-MSCs
changed
to
round
polygonal
addition,
exhibited
levels
hepatocyte-specific
markers,
including
albumin,
cytokeratin-18
(CK-18),
CK-19,
cytochrome
P450
family
1
subfamily
A
(CYP1A1),
CYP1A2,
CYP3A4,
SRY-box
transcription
17
(SOX17),
forkhead
box
A2
(FOXA2).
These
indicate
rhLIGHT
enhances
functional
Furthermore,
rhLIGHT-induced
higher
ability
store
glycogen
uptake
indocyanine
green
compared
control
cells,
indicating
progression.
Additionally,
increased
number,
viability,
proliferation
inducing
S/G2/M
phase
upregulating
expression
various
cyclin
dependent
kinase
(CDK)
proteins.
We
also
found
hepatogenic
induced
was
mediated
activation
signal
transducer
activator
3
(STAT3)
STAT5
pathways.
Overall,
our
findings
suggest
plays
an
essential
role
in
Hence,
may
valuable
Journal of Tissue Engineering,
Год журнала:
2023,
Номер
14
Опубликована: Янв. 1, 2023
Congenital
and
chronic
liver
diseases
have
a
substantial
health
burden
worldwide.
The
most
effective
treatment
available
for
these
patients
is
whole
organ
transplantation;
however,
due
to
the
severely
limited
supply
of
donor
livers
side
effects
associated
with
immunosuppressive
regimen
required
accept
allograft,
mortality
rate
in
end-stage
disease
annually
rising.
Stem
cell-based
therapy
aims
provide
alternative
treatments
by
either
cell
transplantation
or
bioengineered
construct
transplantation.
Human
amnion
epithelial
cells
(AEC)
are
widely
available,
ethically
neutral
source
plasticity
potential
multipotent
stem
immunomodulatory
properties
perinatal
cells.
AEC
been
proven
be
able
achieve
functional
improvement
towards
hepatocyte-like
cells,
capable
rescuing
animals
metabolic
disorders;
they
showed
activities
vitro.
Decellularised
extracellular
matrix
(ECM)
scaffolds
gained
recognition
as
adjunct
biological
support.
maintain
native
ECM
components
3D
architecture
instrumental
organ,
necessary
support
cells’
maturation
function.
We
combined
ECM-scaffold
technology
primary
human
AEC,
which
we
demonstrated
being
equipped
essential
ECM-adhesion
proteins,
evaluated
on
differentiation
into
(HLC).
This
novel
approach
included
use
custom
4D
bioreactor
constant
oxygenation
media
perfusion
cultures
over
time.
successfully
generated
HLC
positive
hepatic
markers
such
ALB,
CYP3A4
CK18.
AEC-derived
displayed
early
signs
hepatocyte
phenotype,
secreted
albumin
urea,
expressed
Phase-1
-2
enzymes.
combination
liver-specific
provides
system
aid
HLC,
indicating
that
innovative
may
pluripotent
important
repercussions
bioengineering
constructs
Journal of Pharmacy & Pharmacognosy Research,
Год журнала:
2024,
Номер
12(4), С. 800 - 813
Опубликована: Март 31, 2024
Context:
Cellular
abnormalities
in
the
ducts
and
breast
tissue
cause
cancer
to
invade
nearby
tissues
like
liver.
The
fibroblast
growth
factor
(FGF)
signals
are
sent
its
receptor
regulate
various
cellular
processes
maintain
liver
homeostasis.
However,
this
condition
has
few
inefficient
treatments.
Breast
is
characterized
by
development
of
within
tissue,
leading
invasion
adjacent
tissues,
such
as
Aims:
To
examine
impact
Rhodomyrtus
tomentosa
administration
on
expression
FGF
family
animal
models,
with
a
specific
focus
Methods:
Cancer
model
rats
were
administered
at
dosages
100,
200,
300
mg/kg
BW
for
30
days.
Liver
blood
serum
samples
extracted
from
rat.
was
stained
immunohistochemistry
using
FGF1,
FGF15,
FGF19,
FGF21,
collected
ELISA
analysis.
Results:
study
found
that
DMBA
hepatocyte
cells
degrades
parenchyma,
making
it
hydrophilic
necrosating.
Hepatocyte
cell
function
improved
greatest
dose
R.
tomentosa.
elevation
associated
an
area
around
portal
vein
where
recently
dividing
hepatocytes
form
clusters.
Conclusions:
promise
candidate
hepatoprotective
medicines
treatment
arises
ability
influence
crucial
health
markers,
including
FGF21.
Stem Cell Reports,
Год журнала:
2024,
Номер
19(6), С. 877 - 889
Опубликована: Май 9, 2024
Liver
disease
is
a
major
global
health
challenge.
There
shortage
of
liver
donors
worldwide,
and
hepatocyte
transplantation
(HT)
may
be
an
effective
treatment
to
overcome
this
problem.
However,
the
present
approaches
for
generation
hepatocytes
are
associated
with
challenges,
interspecies
chimera-derived
produced
by
blastocyst
complementation
(IBC)
promising
donor
because
their
more
comprehensive
hepatic
functions.
In
study,
we
isolated
mouse
from
mouse-rat
chimeric
livers
using
IBC
found
that
exhibited
mature
functions
in
terms
lipid
accumulation,
glycogen
storage,
urea
synthesis.
Meanwhile,
they
were
similar
endogenous
than
derived
vitro.
Interspecies
could
relieve
chronic
fibrosis
reside
injured
after
transplantation.
Our
results
suggest
potentially
reliable
source
can
applied
as
therapeutic
approach
HT.
Current Opinion in Biomedical Engineering,
Год журнала:
2024,
Номер
31, С. 100537 - 100537
Опубликована: Май 16, 2024
The
need
for
organ
transplants
exceeds
donor
availability.
In
the
quest
to
solve
this
shortage,
most
remarkable
area
of
advancement
is
production
through
use
chimeric
embryos,
commonly
known
as
blastocyst
complementation.
This
technique
involves
combination
different
species
generate
chimeras,
where
extent
cell
contribution
desired
tissue
or
can
be
regulated.
However,
ethical
concerns
arise
with
brain
in
such
chimeras.
Furthermore,
ratio
contributed
cells
host
animal
system
low
chimeras
associated
apoptosis.
review
discusses
latest
innovations
complementation
and
highlights
progress
made
creating
organs
transplant.
Biomedical Reports,
Год журнала:
2022,
Номер
16(5)
Опубликована: Март 23, 2022
Directed
differentiation
of
human
induced
pluripotent
stem
cells
(iPSCs)
into
hepatocytes
could
provide
an
unlimited
source
liver
cells,
and
therefore
holds
great
promise
for
regenerative
medicine,
disease
modeling,
drug
screening
toxicology
studies.
Various
methods
have
been
established
during
the
past
decade
to
differentiate
iPSCs
hepatocyte-like
(HLCs)
using
growth
factors
and/or
small
molecules.
However,
direct
comparison
efficiency
quality
final
HLCs
between
different
has
rarely
reported.
In
current
study,
two
hepatocyte
were
devised,
termed
Method
1
2,
through
modifying
existing
well-known
strategies,
resultant
compared
phenotypically
functionally
at
stages
differentiation.
Compared
1,
higher
reproducibility
observed
in
which
generated
highly
homogeneous
functional
end
process.
The
exhibited
morphology
closely
resembling
primary
expressed
high
levels
hepatic
protein
markers.
More
importantly,
these
demonstrated
several
essential
characteristics
mature
hepatocytes,
including
major
serum
(albumin,
fibronectin
α-1
antitrypsin)
secretion,
urea
release,
glycogen
storage
inducible
cytochrome
P450
activity.
Further
transcriptomic
derived
from
identified
1,481
differentially
genes
(DEGs);
290
Gene
Ontology
terms
biological
process
category
enriched
by
genes,
further
categorized
34
classes.
Pathway
analysis
DEGs
signaling
pathways
involved
'signaling
regulating
pluripotency
cells',
'Wnt
pathway',
'TGF-beta
pathway'
'PI3K-Akt
pathway'.
These
results
may
a
molecular
basis
differences
suggest
ways
improve
order
obtain
more
biomedical
applications.
Current Stem Cell Research & Therapy,
Год журнала:
2023,
Номер
19(10), С. 1303 - 1311
Опубликована: Окт. 17, 2023
In
the
last
decade,
liver
diseases
with
high
mortality
rates
have
become
one
of
most
important
health
problems
in
world.
Organ
transplantation
is
currently
considered
effective
treatment
for
compensatory
failure.
An
increasing
number
patients
and
shortage
donors
has
led
to
attention
reconstructive
medicine
methods
researchers.
The
biggest
challenge
development
drugs
chronic
disease
lack
a
suitable
preclinical
model
that
can
mimic
microenvironment
problems.
Organoid
technology
rapidly
evolving
field
enables
researchers
reconstruct,
evaluate,
manipulate
intricate
biological
processes
